Mind Medicine Inc.’s $34.5 Million Bought Deal Prospectus Offering

Wildeboer Dellelce LLP acted for MindMed in connection with the offering.

Mind Medicine Inc., a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and experiential therapies to address addiction and mental illness, completed a bought deal prospectus offering of 18,170,000 units for aggregate gross proceeds of $34,523,000. The offering was conducted by Canaccord Genuity Corp., as lead underwriter, and Eight Capital.

The Wildeboer Dellelce team comprised of Perry Dellelce (Picture), Peter Volk, Rebecca Cochrane and Katie Drury (corporate/securities) and Katy Pitch and Marija Tasevska (tax).

Involved fees earner: Rebecca Cochrane – Wildeboer Dellelce LLP; Perry Dellelce – Wildeboer Dellelce LLP; Katy Pitch – Wildeboer Dellelce LLP; Marija Tasevska – Wildeboer Dellelce LLP; Peter Volk – Wildeboer Dellelce LLP;

Law Firms: Wildeboer Dellelce LLP;

Clients: Mind Medicine Inc;


Author: Ambrogio Visconti